Adalimumab
Adalimumab is a TNF-alpha inhibitor. Current EMA product information requires evaluation for both active and latent tuberculosis before treatment starts, because an existing — even silent — infection can reactivate under this drug class.
Preparing for your first biologic dose
Before Your First Biologic Dose
What commonly matters between deciding on a biologic and the first dose — organised, instead of scattered across several sources.
A private preparation checklist for your next appointment — TB screening, vaccination, medical history and practical questions in one place.
“What needs to be settled before my first injection?”
As soon as a biologic is proposed, several questions tend to show up at once: was a TB test done? Does vaccination status need reviewing? Does an earlier condition matter? Who shows me how to use it?
This page collects those questions in one place, keeping what applies to every biologic separate from what matters specifically for adalimumab, secukinumab or bimekizumab.
No account, nothing stored on a server, and no assessment of your answers.
What commonly matters before starting a biologic
Secukinumab
Current secukinumab product information warns about new or worsening inflammatory bowel disease and advises against giving live vaccines at the same time.
Bimekizumab
Current bimekizumab product information asks patients to discuss previous inflammatory bowel disease, recurrent infection, previous tuberculosis and planned vaccination. Oral candidiasis (thrush) is among the more common side effects.
What commonly matters before starting a biologic
The gap between the decision and the first dose
As soon as a clinician proposes starting a biologic, a short, dense phase usually follows: blood tests, tuberculosis screening, a review of vaccination status, training in how to use the medicine, and a prescription — often spread across several appointments.
This page replaces none of those appointments. It helps gather the questions and information that commonly come up, so less of it gets lost between appointments.
Why tuberculosis screening matters
TB screening before starting a biologic for HS is explicitly recommended in current guidance for special patient populations. It matters particularly with TNF-alpha inhibitors such as adalimumab, because an existing — even silent — TB infection can reactivate under this drug class.
Current EMA product information for Humira, Cosentyx and Bimzelx consistently names active tuberculosis or other serious infections as a reason to delay or adjust the start of treatment — the exact assessment is made by the treating clinician.
Why vaccination status matters before treatment starts
According to the Robert Koch Institute, non-live vaccines can generally be given during immunosuppressive treatment, even though the immune response is sometimes weaker. Live vaccines, by contrast, should generally be given before such treatment starts and are usually contraindicated during relevant immunosuppression; the RKI states they can generally be given up to four weeks before treatment begins.
Secukinumab and bimekizumab product information therefore specifically advise against giving certain live vaccines at the same time. Which vaccinations are appropriate for you personally depends on age, history and risk profile — this page therefore deliberately names no universal vaccine list.
Active infections and other health questions
All three biologics approved for HS — adalimumab, secukinumab and bimekizumab — must not be used, according to current EMA information, during a serious or clinically significant active infection. Whether an existing infection, recurrent infections or a planned procedure changes the timing of the first dose is a decision for the treating clinician.
Why the three biologics are not interchangeable
Adalimumab needs particular attention to tuberculosis because of the reactivation risk, and is not used in certain grades of heart failure; previous hepatitis B is also something worth raising.
Secukinumab and bimekizumab both warn about new or worsening inflammatory bowel disease. Bimekizumab additionally names oral candidiasis (thrush) as one of the more common side effects.
A generic sentence such as “biologics suppress the immune system” does not convey these differences. Select your prescribed medicine in the tool to see the points that apply to it.
Why a baseline before the first dose helps
Biologics usually work over weeks, not days. Describing how severe the condition was only weeks after starting treatment relies on memory — which often underestimates how bad things were before.
A short baseline before the first dose — affected areas, pain, drainage, daily impact — makes the later conversation about whether treatment is working more concrete, without needing a clinical score.
When is the effect reviewed?
Current secukinumab and bimekizumab product information names a decision point around week 16 of treatment for assessing whether an adequate response has been reached. That is not a reason to judge the first injections “not working”.
The exact timing depends on the specific medicine and individual circumstances. This page therefore sets no single universal review date — it only records whether a date or timeframe has already been agreed with your treatment team.
What this tool cannot establish
It does not decide whether a biologic is suitable or safe for you, it interprets no laboratory result, and it gives no instruction to skip or delay a dose. It produces no “ready to start” statement or anything equivalent.
What it can do: show you which topics commonly come up when starting this kind of treatment, and help you take the matching questions to your next appointment.
What these pages are not for
- They do not decide whether a biologic is safe or suitable for you.
- They do not interpret laboratory results or test outcomes.
- They give no instruction to skip, delay or change a dose.
- They do not replace a medical examination or a training appointment.
Ready for your next appointment?
The checklist records what is already done and what you still want to raise, in a few minutes.
Open the checklistCommon questions
If I complete everything, does that mean I am cleared to start?
No. This tool never makes that decision. It only builds a list of the points you want to raise yourself with your treatment team.
My biologic is not in the list — what now?
Choose “Another biologic”. The tool does not guess which rules apply to your medicine — it records that you want to ask about this explicitly.
Who decides about TB screening and vaccination?
Your treating clinician, not this website. The tool explains why these topics come up frequently and helps you raise them.
Does this examine or assess me in any way?
No. There is no score, no result and no evaluation of your answers. You decide what appears on the sheet.
Where are my answers stored?
Only in the memory of your open browser tab — no account, nothing sent to a server of this website, and no link anyone could open. Reloading clears the sheet immediately.
I have already started treatment — is this tool still useful?
It is most useful before the first dose. Individual sections — such as the baseline or the follow-up timeframe — can still be useful later, though.
Evidence and editorial review
Last editorially reviewed: · Next review:
Drug-specific details checked:
The statements about TB screening, active infection and vaccination rest on current EMA product information for Humira, Cosentyx and Bimzelx, and on Robert Koch Institute guidance on vaccination during immunosuppression.
Product information can change. The drug-specific content is therefore reviewed every six months — faster than the rest of the text on these pages.
Nothing on these pages replaces the individual assessment made by your treating clinician, and no selection in the checklist produces a recommendation to start, delay or skip a treatment.
Related on this site
My HS Home Your appointment questions, saved tools and more in one place — no account needed. Treatment Options for Acne Inversa The treatment classes at a glance, with biologics as one of several layers. Prepare a treatment conversation A neutral tool to record what matters to you and build questions for the appointment. My HS care team Who may be involved in HS care and how appointments can be coordinated. Track your symptoms A baseline here can also be continued as ongoing tracking. Find an HS specialist Dermatology practices with HS experience in Germany. When to get medical help The page to fall back on whenever it is unclear whether something needs looking at soon.
Sources
- Humira (adalimumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
- Humira — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
- Cosentyx (secukinumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
- Cosentyx — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
- Bimzelx (bimekizumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
- Bimzelx — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
- Contraindications and vaccination under immunosuppression — frequently asked questions Robert Koch Institute (RKI), Germany · Checked: 2026-08-25
- Recommendations for tuberculosis screening before biologic therapy in special patient populations with hidradenitis suppurativa PubMed, US National Library of Medicine · Checked: 2026-08-25
- Hidradenitis suppurativa: Diagnosis and treatment American Academy of Dermatology (AAD) · Checked: 2026-08-25